Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Rosacea
Interventions: Doxycycline, Metronidazole, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress Disorders, Post-Traumatic
Interventions: Lorazepam 1 mg tablet, Placebo tablet; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Menopause
Interventions: DR-2041a, DR-2041b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 97
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more

Conditions: Cocaine Abuse, Cocaine-Related Disorders
Interventions: Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aspergillosis
Interventions: voriconazole, anidulafungin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more

Conditions: Schizophrenia
Interventions: Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d; Drug
Lead sponsor: Donald C. Goff, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more

Conditions: Radiation-induced Dermatitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo; Behavioral · Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Traumatic Brain Injury
Interventions: Placebo, Sertraline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cocaine Dependence
Interventions: Modafinil, Sugar Pill, Contingency Management, Methadone, cognitive behavioral treatment, Voucher Control; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions: depot leuprolide acetate 3.75 mg, Placebo; Drug
Lead sponsor: Joseph Mccune; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Opioid-use Disorder
Interventions: Intranasal Oxycodone, Cue Session; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 59 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Raynaud's Disease, Peripheral Vascular Disease
Interventions: PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more

Conditions: Pain Management
Interventions: MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Parkinson's Disease, Gait Impairment
Interventions: Methylphenidate (MPD), Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 35 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cirrhosis, Liver
Interventions: Epigallocatechin gallate (EGCG), Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
Interventions: Foralumab Nasal, Placebo; Drug
Lead sponsor: Tiziana Life Sciences LTD; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Davie, Florida • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Opioid Dependence, Opioid Withdrawal
Interventions: Intranasal Oxytocin Spray, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Esuberaprost, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more

Conditions: Myeloma
Interventions: Minocycline, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease
Interventions: DNL747, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more

Search by objective public record fields.

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Platelet Rich Plasma Injections In Young And Old Human Subjects

Computational Assessment of GABA Receptor Modulation in PTSD

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Medications for Stopping Cocaine Dependence and Preventing Relapse

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Pharmacotherapy & CM for Opioid and Cocaine Dependence

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

PF-00489791 For The Treatment Of Raynaud's

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

EGCG for Hepatocellular Carcinoma Chemoprevention

The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab

Oxytocin Treatment of Opioid Dependence

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease